8月13日诺华通过其微信公众号宣布ianalumab(VAY736)用于活动性干燥综合征成人患者的III期临床试验取得积

智通财经
Aug 13
8月13日诺华通过其微信公众号宣布ianalumab(VAY736)用于活动性干燥综合征成人患者的III期临床试验取得积极结果。两项试验均达到了主要终点显示其针对疾病活动性具有统计学意义的显著改善。这些结果支持ianalumab作为一种具有双重作用机制(B细胞清除和BAFF-R抑制)的药物有望成为首个针对干燥综合征患者的靶向治疗方案。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10